01 7ASTRAZENECA AB
01 78685934
01 7Blank
01 7Blank
01 72030-05-26
Patent Expiration Date : 2030-05-26
US Patent Number : 8685934
Drug Substance Claim :
Drug Product Claim :
Application Number : 202293
Patent Use Code : U-1522
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2030-05-26
Patent Expiration Date : 2030-05-26
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
US Patent Number : 8685934
Drug Substance Claim :
Drug Product Claim :
Application Number : 205649
Patent Use Code : U-1522
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2030-05-26
Patent Expiration Date : 2030-05-26
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
US Patent Number : 8685934
Drug Substance Claim :
Drug Product Claim :
Application Number : 205649
Patent Use Code : U-1522
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2030-05-26
Patent Expiration Date : 2030-05-26
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
US Patent Number : 8685934
Drug Substance Claim :
Drug Product Claim :
Application Number : 205649
Patent Use Code : U-1522
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2030-05-26
Patent Expiration Date : 2030-05-26
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
US Patent Number : 8685934
Drug Substance Claim :
Drug Product Claim :
Application Number : 205649
Patent Use Code : U-1522
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2030-05-26
Patent Expiration Date : 2030-05-26
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
US Patent Number : 8685934
Drug Substance Claim :
Drug Product Claim :
Application Number : 205649
Patent Use Code : U-1522
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2030-05-26
Patent Expiration Date : 2030-05-26
US Patent Number : 8685934
Drug Substance Claim :
Drug Product Claim :
Application Number : 202293
Patent Use Code : U-1522
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2030-05-26
